Dantrolene in Human Malignant Hyperthermia A Multicenter Study

  title={Dantrolene in Human Malignant Hyperthermia A Multicenter Study},
  author={Mary Elizabeth Kolb and M. L. Horne and Robert C. Martz},
Anesthesiologists from 65 institutions participated in a multicenter study to assess the efficacy of lyophilized intravenous dantrolene sodium in treating anesthetically related malignant hyperthermia (MH). Of 21 patients treated with the drug, eight were judged to have unequivocal MH and were treated according to study protocol. Three were judged to have probable MH and were also treated according to study protocol. All 11 recovered without sequelae from MH and without adverse drug effects. A… 
Clinical effects of intravenously administered dantrolene.
The presence of side effects does not outweigh the usefulness of this drug in treating malignant hyperthermia, but it may be a consideration in deciding whether to administer dantrolene prophylactically before surgical procedures in known or suspected MHS patients.
Cardiopulmonary bypass interference with dantrolene prophylaxis of malignant hyperthermia.
Serial blood dantrolene levels in an MH-susceptible child who underwent cardiac surgery with CPB are reported, finding that immediate therapy with adequate doses of dantolene can be lifesaving.
Safe Duration of Postoperative Monitoring for Malignant Hyperthermia Patients Administered Non-Triggering Anaesthesia: An Update
Standard postoperative monitoring times are safe and appropriate in MH-susceptible patients, as evaluated over a series of three studies.
Postoperative malignant hyper-thermia and dantrolene therapy
The unusual occurrence of MH in the postoperative period, when the major effects of anaesthesia were no longer an important consideration, is discussed with regard to the “human stress syndrome”.
Reevaluation by Clinical Grading Scale for Malignant Hyperthermia Reported in Korean Journal of Anesthesiology
This work attempted to reevaluate the MH in Korea using a Clinical Grading Scale (CGS) developed by Larach and colleagues to assist in clinical diagnosis and for establishing a national registry system.
Incidence of malignant hyperthermia reactions in 2,214 patients undergoing muscle biopsy
It is concluded that the incidence of MH reactions in biopsy-positive patients who receive a trigger-free anaesthetic for minor surgery is small and these reactions occur in the immediate postoperative period.
Malignant Hyperthermia in the Otolaryngologic Patient: Prospective Anesthetic and Surgical Management of Eight Children
This study demonstrates that patients at risk of developing MH crisis can have otolaryngologic procedures performed relatively safely while undergoing appropriately selected anesthesia.
Clinical Presentation, Treatment, and Complications of Malignant Hyperthermia in North America from 1987 to 2006
Elevated temperature may be an early malignant hyperthermia sign and accurate temperature monitoring during general anesthetics and early dantrolene administration may decrease the 35% MH morbidity rate.
Prevalence of Malignant Hyperthermia Due to Anesthesia in New York State, 2001–2005
The prevalence of MH due to anesthesia in surgical patients treated in New York State hospitals is approximately 1 per 100,000, and MH risk in males is significantly higher than in females.
Analysis of the Clinical Variables Associated with Recrudescence after Malignant Hyperthermia Reactions
Muscular body types had a higher rate of recrudescence, perhaps associated with increased muscle mass, and time from induction to initial malignant hyperthermia reaction increased, perhaps as a result of greater muscle exposure to triggering agents.